Clinical Trials Regeneron’s antibody cocktail helps prevent and treat Covid-19 in Phase III studies 13 Apr 2021
Clinical Trials Regeneron’s antibody cocktail helps prevent and treat Covid-19 in Phase III studies 13 Apr 2021
06 Apr 2021 Comment Provention’s success with T1D-delaying mAb will contend with field’s need to develop screening protocols and ensuing cumulative costs, experts say 06 Apr 2021
01 Apr 2021 Comment Janssen’s amivantamab has competitive edge over Spectrum’s and Takeda’s exon 20 mutation directed TKIs in NSCLC 01 Apr 2021
29 Mar 2021 Comment Provention’s FDA AdCom for mAb to delay T1D likely to home in on safety profile but strong efficacy buoys regulatory prospects 29 Mar 2021
19 Mar 2021 Comment Sanofi’s, AstraZeneca’s and Radius’ oral SERDs could establish clinical worth in ER+ breast cancer by showing similar efficacy to Faslodex, experts say 19 Mar 2021
01 Mar 2021 Comment AbbVie’s plan to push Rinvoq to counter Humira biosimilar surge dampens after questions on JAK inhibitor class safety, biosimilar uptake still a challenge 01 Mar 2021
01 Mar 2021 Comment Humanigen’s and Kiniksa’s anti-GM-CSF antibodies likely to garner a place for nonventilated Covid-19 patients; mixed views on ideal timepoint to measure clinical improvements 01 Mar 2021
22 Feb 2021 Comment LoA Update: BMS’ Opdivo LoA score drops by 13 points in endometrial cancer following investigator-led Phase Ib/IIa study termination 22 Feb 2021
18 Feb 2021 Comment LoA Update: Regeneron’s Libtayo LoA score shoots up 20 points following Phase III NSCLC results publication 18 Feb 2021
12 Feb 2021 Comment New SARS-CoV-2 variants push Covid-19 vaccine long-term durability questions to back seat 12 Feb 2021
11 Feb 2021 Comment Sorrento enrols 60 of 80-patient Phase II target for abivertinib in Covid-19; futility analysis potentially in a month, CEO says 11 Feb 2021
